Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00702325 · ClinicalTrials.gov registry record · Phase 4
Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 311
- Enrollment target
NCT00702325 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 311 participants.
The verdict
NCT00702325, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 311 participants
- Enrollment target
Study Summary
To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma.
Interventions
- DRUG Budesonide
- DRUG Budesonide / formoterol fumarate (SYMBICORT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00702325
The ClinicalTrials.gov registry entry for NCT00702325 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Budesonide is the first listed.
NCT00702325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00702325 about?
NCT00702325 is a clinical study titled "Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans". To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma.
What is the current status of trial NCT00702325?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 311 participants. The study started on 2008-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00702325?
The interventions under investigation include: Budesonide (DRUG), Budesonide / formoterol fumarate (SYMBICORT) (DRUG).
Who is sponsoring clinical trial NCT00702325?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.